Drug companies are incentivized to find new uses for existing drugs rather than discover new ones, which is a serious problem in the pharmaceutical industry.

The big pharmacy benefit managers prioritize profits over everything, operating in an opaque industry where they can manipulate prices without accountability.

Insurance companies and pharmacy benefit managers (PBMs) often dictate which medications are authorized, sometimes requiring patients to try cheaper alternatives first, regardless of their effectiveness.

Pharmacy benefit managers often prevent access to cheaper biosimilars like YUSIMRY because they do not receive rebates on them, prioritizing profit over patient savings.

Biotech companies need a period of exclusivity around their intellectual property to recover their investments before generics enter the market.

The big three PBMs are not reimbursing local pharmacies adequately, causing many to go out of business, which is detrimental to community healthcare.

The pharmaceutical industry has a low probability of success, around 10%, which drives the need for AI to improve efficiency in drug discovery and development processes.

The big three pharmacy benefit managers will not disclose their pricing structures, making it impossible for clients to know if they are being charged fairly.

The future of biotech will likely involve products that patients are willing to pay for, focusing on conditions that significantly impact their quality of life.